← Back to headlines
Deutsche Bank Upgrades Merck to Buy, Sees Clear Path Beyond Keytruda Patent Cliff
Deutsche Bank has upgraded Merck (MRK) to a 'Buy' rating, expressing optimism about the company's future beyond the patent expiration of its key drug, Keytruda.
20 Feb, 23:31 — 20 Feb, 23:31
ℹOnly 1 source covers this story
Read at source (1 outlet)
Related Stories
Investment Strategy: Turning Monthly Savings into $1 Million with Financial Services Stock
4m ago
Fed’s Hammack: Monetary Policy Is in a Good Place to Stay on Hold - The Wall Street Journal
13m ago
Analysts Offer Insights on Materials Companies Nutrien, Gold Fields, and First Majestic Silver
13m ago
Tech Giants AMZN, MSFT, NVDA, SFTBY Face Significant Financial Impact
13m ago